BIIB
Biogen·NASDAQ
--
--(--)
--
--(--)
BIIB fundamentals
Biogen (BIIB) released its earnings on Feb 6, 2026: revenue was 2.28B (YoY -7.16%), beat estimates; EPS was 1.99 (YoY -42.15%), beat estimates.
Revenue / YoY
2.28B
-7.16%
EPS / YoY
1.99
-42.15%
Report date
Feb 6, 2026
BIIB Earnings Call Summary for Q4,2025
- Growth Products Dominate: 2025 growth products ($3.3B) outpaced MS decline, with LEQEMBI ($134M Q4 sales), ZURZUVAE, and VUMERITY leading.
- Pipeline Momentum: 10 Phase III programs, including litifilimab (SLE), felzartamab (AMR), and BIIB080 (tau ASO), set to deliver data in 2026-2027.
- Strategic Acquisitions: Alcyone Therapeutics to enhance SPINRAZA delivery; $2.1B free cash flow supports R&D and launches.
- 2026 Outlook: Non-GAAP EPS $15.25-$16.25, revenue decline offset by growth products; lupus and nephrology launches key to future growth.
EPS
Actual | 9.14 | 10.26 | 8.84 | 4.58 | 5.34 | 5.68 | 4.77 | 3.39 | 3.62 | 5.25 | 4.77 | 4.05 | 3.4 | 4.02 | 4.36 | 2.95 | 3.67 | 5.28 | 4.08 | 3.44 | 3.02 | 5.47 | 4.81 | 1.99 | ||||||||||||||||
Forecast | 7.7242 | 8.0221 | 8.0863 | 4.7917 | 4.9815 | 4.5491 | 4.0862 | 3.377 | 4.3401 | 4.0602 | 4.1258 | 3.4891 | 3.2782 | 3.7765 | 3.9735 | 3.184 | 3.4695 | 4.068 | 3.7724 | 3.3313 | 2.8993 | 3.8986 | 3.8824 | 1.6251 | ||||||||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +18.33% | +27.90% | +9.32% | -4.42% | +7.20% | +24.86% | +16.73% | +0.38% | -16.59% | +29.30% | +15.61% | +16.08% | +3.72% | +6.45% | +9.73% | -7.35% | +5.78% | +29.79% | +8.15% | +3.26% | +4.16% | +40.31% | +23.89% | +22.45% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.53B | 3.68B | 3.38B | 2.85B | 2.69B | 2.77B | 2.78B | 2.73B | 2.53B | 2.59B | 2.51B | 2.54B | 2.46B | 2.46B | 2.53B | 2.39B | 2.29B | 2.46B | 2.47B | 2.45B | 2.43B | 2.65B | 2.53B | 2.28B |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.42B | 3.43B | 3.33B | 2.80B | 2.65B | 2.61B | 2.67B | 2.62B | 2.50B | 2.47B | 2.47B | 2.45B | 2.34B | 2.37B | 2.40B | 2.47B | 2.31B | 2.39B | 2.43B | 2.41B | 2.23B | 2.33B | 2.34B | 2.20B |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +3.25% | +7.34% | +1.24% | +2.00% | +1.64% | +6.35% | +4.11% | +4.34% | +1.28% | +4.66% | +1.60% | +4.04% | +5.18% | +3.77% | +5.44% | -3.23% | -0.80% | +3.03% | +1.29% | +1.93% | +8.81% | +13.63% | +8.32% | +3.46% |
Earnings Call
You can ask Aime
What is Biogen's latest dividend and current dividend yield?What were the key takeaways from Biogen's earnings call?What were the key takeaways from Biogen’s earnings call?What is Biogen's gross profit margin?Did Biogen beat or miss consensus estimates last quarter?What does Biogen do and what are its main business segments?What guidance did Biogen's management provide for the next earnings period?What factors drove the changes in Biogen's revenue and profit?
